SCHEMBL5690507

SCHEMBL5690507

OC1(c2ccc(OCc3ccccc3)cc2)CCC2(CC1)OCCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
PTGS1 P23219 1/20 0.47
SLC6A2 P23975 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTGS2 P35354 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HIF1A Q16665 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
GRIN1 Q05586 1/20 0.45
GRIN2B Q13224 1/20 0.45
MAOB P27338 5/20 0.44
NR4A1 P22736 1/20 0.43
NR4A2 P43354 1/20 0.43
NR4A3 Q92570 1/20 0.43
CCR1 P32246 1/20 0.43
MAOA P21397 2/20 0.43
GAA P10253 2/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19339365 0.89 GRIN1 (0.48) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL2016642 0.85 ALOX5 (0.53) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL16553890 0.83 LMNA (0.56) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6698643 0.82 P4HTM (0.45) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL2508947 0.82 GABRA5 (0.44) GRIN1GRIN2B
SCHEMBL21874079 0.82 LMNA (0.51) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL3133827 0.82 LMNA (0.51) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL17072362 0.81 LMNA (0.54) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL10041856 0.81 LMNA (0.54) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL11059742 0.81 MAOB (0.48) LMNACYP1A2PTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0982026-B1 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers HOFFMANN LA ROCHE (CH) 2006-05-17 EP disclosed
US-6184236-B1 Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative HOFFMANN-LA ROCHE INC. 2001-02-06 US disclosed
EP-0982026-A2 Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers F. HOFFMANN-LA ROCHE AG (CH) 2000-03-01 EP disclosed